Assessment of risk compensation following use of the dapivirine vaginal ring in southwestern Uganda

Abstract
Objectives: Participation in HIV prevention trials could trigger risk compensation among participants. We evaluated potential risk compensation following use of a vaginal ring microbicide by women in a phase III trial in southwestern Uganda.Methods: We used markers of sexual risk behaviour documented on standardised questionnaires, tested for STIs at baseline and quarterly for 2 years. Risk compensation was defined as a significant increase (trend pTrichomonas vaginalis pNeisseria gonorrhoeae p<0.001Conclusions: No evidence of risk compensation was observed in this trial.Trial registration number: NCT01539226.
Funding Information
  • International Partnership for Microbicides (IND # 110,659)